Active Research Trials

Breast

Trial Name: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Trial Number: A012103

Trial Name: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Trial Number: NRG-BR007  

Trial Name: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)
Trial Number: NRG-BR008

Trial Name: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Trial Number: S2206 

Trial Name: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
Trial Number: S2212

Lung

Trial Name: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Trial Number: A151216

Trial Name: Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Trial Number: A081801 (ALCHEMIST Subtrial)

Trial Name: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Trial Number: S1827  

Trial Name: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Trial Number: EA5182

Trial Name: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Trial Number: EA5221

Gastrointestinal

Trial Name: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Trial Number: NRG-GI008

Trial Name: FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
Trial Number: NRG-CC005

Trial Name: The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Trial Number: A022106

Trial Name: Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
Trial Number: A022102

Trial Name: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer
Trial Number: A022104 

All Cancer

Trial Name: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Trial Number: S2013

Trial Name: Olanzapine Ver]sus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Trial Number: A222004

Trial Name: Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
Trial Number: URCC-18007 

Gynecology

Hematology

Trial Name: A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Trial Number: S2209

Trial Name: A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Trial Number: A052101 

Melanoma

Trial Name: A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Trial Number: EA6192

NOTE: Trials open and close regularly at different times. To make sure a trial is still open, call 219-836-6875.

It takes 14 years for an experimental drug to travel from the laboratory to U.S. consumers. The longest part of that process is finding people to participate in each phase of clinical trials. The more people who take part, the faster we will find better ways to treat and prevent cancer.

The purpose of the cancer research clinical trials offered at our local hospitals is to gather and evaluate information about new medications that are not yet approved by the FDA. Sometimes, a clinical trial will involve a drug already approved by the FDA for one purpose, but that is being evaluated for another use.

It is important to note that every person participating in a cancer clinical trial receives treatment. While the word placebo may be included in the trial description, patients receive, at minimum, the best standard treatment in conjunction with the study medications. Placebo in these cases does NOT mean the patient is not receiving any treatment.

People choose to participate in clinical trials for many reasons. Some have exhausted all other therapy options and wish to try experimental treatment to help prolong or improve quality of life. Others wish to have access to new therapies that may benefit them, with faster healing or less side effects. Still others feel a strong sense of commitment to helping advance cancer research and help identify new therapies for those diagnosed in the future.

The Community Cancer Foundation sponsors research trials at the three acute care hospitals of Powers Health: Community Hospital in Munster; St. Catherine Hospital in East Chicago; and St. Mary Medical Center in Hobart. The Foundation provides area residents with access to...

• Phase II clinical trials sponsored by the Hoosier Oncology Group (HOG) for a variety of metastatic cancers.
• Phase III clinical trials sponsored by the Cancer Trials Support Unit (CTSU) supported by the National Cancer Institute for most cancer sites.
• Other clinical trials sponsored by pharmaceutical companies.